Purified transfected mouse B7-DC cell line
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at – 20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this CD273 antibody clone TY25 for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Other Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone TY25 recognizes an epitope on mouse PD-L2. TY25 does not cross-react with PD-L1.
PD-L2 is expressed on macrophages and a subset of dendritic cells (DCs).
PD-L2 antibody, clone TY25, recognizes mouse programmed death ligand 2 (PDL-2), also known as B7-DC and CD273. PD-L2 is a 42 kDa type I transmembrane glycoprotein that belongs to the B7 family of the immunoglobulin (Ig) receptor superfamily. PD-L2 is an inhibitory ligand primarily expressed on antigen-presenting cells, including macrophages and a subset of dendritic cells (DCs). Its receptor, PD-1, is expressed by CD4-CD8- thymocytes as well as CD4 and CD8 T cells, monocytes, DCs, and B cells upon activation1. Binding of PD-L2 to PD-1 on CD4 and CD8 T cells inhibits T cell receptor (TCR) signaling, negatively regulating T cell proliferation, cytokine production, and cytotoxic activity2. PD-L2 is expressed on many tumor types3,4 and is associated with unfavorable prognosis in patients with solid tumors5.
PD-1, uncharacterized receptor
NCBI Gene Bank ID
References & Citations
1. Francisco LM, et al. (2010) Immunol Rev. 236:219-242
2. Latchman Y, et al. (2001) Nat Immunol. 2(3):261-8
3. Ahmad SM, et al. (2018) Oncoimmunology. 7:e1390641
4. Panjwani PK, et al. (2018) Hum Pathol. 71:91–9
5. Yang H, et al. (2019) Front Oncol. 9:47
Products are for research use only. Not for use in diagnostic or therapeutic procedures.